• Who We Are
    • About Us
    • Contact Us
    • Member Partners
  • News
    • Latest News
    • Letters
    • Newsletters
    • Press Releases
    • Recent Events
  • The Issue
    • Interchangeable Biosimilars
    • Inflation Reduction Act (IRA)
    • Naming
    • Biologic Safety
    • BIO Principles
    • Non-Medical Switching
  • Policy
    • Australia
    • Canada
    • FDA
    • FDA Guidance
    • In the States
  • Resources
    • Surveys
    • Courses
    • Webinars
    • Approvals
    • Whitepapers
  • Blog
  • Videos

Safe Biologics

  • Safe Biologics

  • Who We Are
    • About Us
    • Contact Us
    • Member Partners
  • News
    • Latest News
    • Letters
    • Newsletters
    • Press Releases
    • Recent Events
  • The Issue
    • Interchangeable Biosimilars
    • Inflation Reduction Act (IRA)
    • Naming
    • Biologic Safety
    • BIO Principles
    • Non-Medical Switching
  • Policy
    • Australia
    • Canada
    • FDA
    • FDA Guidance
    • In the States
  • Resources
    • Surveys
    • Courses
    • Webinars
    • Approvals
    • Whitepapers
  • Blog
  • Videos
Background Image

ASBM One Pagers

About ASBM
asbm-promo-document-eng-042418-e

Basics
roadshow-1p-basics-041818-electronic

Naming
roadshow-1p-naming-041818-electronic

Substitution
roadshow-1p-substitution-071618-elec

Labeling
roadshow-1p-labeling-042418

Extrapolation
roadshow-1p-extrapolation-042418-e

Membership
1p-membership-071618-e

 

Latest News

FDA Chaos Threatens Administration’s Drug Agenda and Risks Patient Safety

Washington Examiner (Opinion): FDA Chaos Threatens Administration’s Drug Agenda and Risks Patient Safety March 15, 2026 | Dr. Cristina Beato  The Trump Administration recently celebrated one year of embracing the movement to Make America Healthy Again. Unfortunately, many of these successes are overshadowed by slapdash decision-making at a key health agency, which significantly undermines the Administration’s goals, threatens treatment […]

Read More

ASBM Statement Commending Senator Jim Banks for Introducing the SAFE Drugs Act of 2025

Download PDF version here February 16, 2026 The Alliance for Safe Biologic Medicines (ASBM) commends Senator Jim Banks (R-IN) for introducing the Safeguarding Americans from Fraudulent and Experimental Drugs (SAFE Drugs) Act of 2026 in the United States Senate. We also support the bipartisan companion bill (H.R. 6509), introduced in the House of Representatives by […]

Read More

ASBM Statement on FDA Commissioner’s Comments Regarding Compounded Medicines

February 6, 2026 The Alliance for Safe Biologic Medicines (ASBM) welcomes FDA Commissioner Marty Makary’s comments on the social media platform X affirming that “the FDA cannot verify the quality, safety, or effectiveness of non-approved drugs” and warning that the agency will “take swift action against companies mass-marketing illegal copycat drugs.” These remarks accurately reflect […]

Read More

logo logo logo
logo

The Alliance for Safe Biologic Medicines (ASBM) is a diverse coalition of stakeholders working worldwide to shape policies that reflect the best interests of patients, ensuring access to lifesaving and life-enhancing medicines while fostering innovation in healthcare.

Contact Us

Who we are
  • About Us
  • Contact Us
  • Member Partners
  • International Advisory Board
News
  • Latest News
  • Letters
  • Newsletter
  • Press Releases
  • Recent Events
The Issue
  • Interchangeable Biosimilars
  • Inflation Reduction Act (IRA)
  • Naming
  • Substitution Policy
  • Biologic Safety
  • BIO Principles
Policy
  • Australia
  • Canada
  • European Union
  • FDA
  • FDA Guidance
  • In the States
Resources
  • Surveys
  • Courses
  • Webinars